Cancer Treatment Reviews
Volume 25, Issue 4 , Pages 187-197 , August 1999

Primary chemotherapy or hormonotherapy for patients with breast cancer

  • Etienne G.C. Brain

      Affiliations

    • Department of Medical Oncology, Cancer Centre René Huguenin, 35, rue Dailly, Saint-Cloud, 92210, France
    • ,
  • Jean-Louis Misset

      Affiliations

    • Department of Medical Oncology, Paul Brousse Hospital, 14, avenue Paul Vaillant Couturier, Villejuif, 94800, France
    • ,
  • Jacques Rouëssé

      Affiliations

    • Department of Medical Oncology, Cancer Centre René Huguenin, 35, rue Dailly, Saint-Cloud, 92210, France

References 

    REFERENCES
  1. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res. 1983;43:1488–1492
  2. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res. 1979;39:3861–3865
  3. O’Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996;2:689–692
  4. Swain SM. Selection of therapy for stage III breast cancer. Surg Clin North America. 1990;70:1061–1080
  5. Jaiyesimi IA, Buzdar AU, Hortobagyi GN. Inflammatory breast cancer: a review. J Clin Oncol. 1992;10:1014–1024
  6. Danforth D, Jacobson J, O’Shaughnessy J. Effect of preoperative chemotherapy on axillary lymph node metastases in stage II breast cancer: a propspective randomized trial. Proc Am Soc Clin Oncol. 1995;14:
  7. Fisher B, Bryant J, Wolmark N. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–2685
  8. Gazet JC, Ford HT, Bland JM, Markopoulos Ch, Coombes RC, Dixon RC. Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet. 1988;1:679–681
  9. Makris A, Powles TJ, Ashley SE. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol. 1998;9:1179–1184
  10. Mauriac L, Durand M, Avril A, Dilhuydy JM. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann Oncol. 1991;2:347–354
  11. Mauriac L, Mac Grogan G, Avril A. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with 124-month median follow-up. Ann Oncol. 1999;
  12. Powles TJ, Hickish TF, Makris A. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 1995;13:547–552
  13. Roberston JFR, Ellis IO, Elston CW, Blamey RW. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer. 1992;28A:908–910
  14. Roberston JFR, Todd JH, Ellis IO, Elston CW, Blamey RW. Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer. Br Med J. 1988;297:511–514
  15. Scholl SM, Asselain B, Beuzeboc P. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery. An update. Proc Am Soc Clin Oncol. 1995;14:
  16. Scholl SM, Fourquet A, Asselain B. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results if a randomised trial: S6. Eur J Cancer. 1994;30A:645–652
  17. Semiglazov VF, Topuzov EE, Bavli JL. Primary (neoadjuvant) chemotherapy and radiotherapy compared with radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol. 1994;5:591–595
  18. Williams MR, Gilson D, Marsh L. The early results from a randomised study of radiotherapy versus Nolvadex (tamoxifen) as initial treatment for stage III breast cancer. Eur J Surg Oncol. 1988;14:235–240
  19. Bonadonna G, Veronesi U, Brambilla C. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990;82:1539–1545
  20. Eisen T, Smith IE, Johnston S. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. J Clin Oncol. 1998;16:1350–1357
  21. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986;46:2578–2581
  22. Smith IE, Walsh G, Jones A. High complete remission rates with primary neoadjuvant chemotherapy for large early breast cancer. J Clin Oncol. 1995;13:424–429
  23. Bonadonna G, Valagussa P, Brambilla C. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol. 1998;16:93–100
  24. Brain E, Garrino C, Misset J-L. Long term prognostic and predictive factors in 107 stage II–III breast cancer patients treated with anthracycline based neoadjuvant chemotherapy. Br J Cancer. 1997;75:1360–1367
  25. Honkoop AH, van Diest PJ, de Jong JS. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer. 1998;77:621–626
  26. Kuerer HM, Newman LA, Smith TL. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–469
  27. Pierga JY, Mouret E, Asselain B. Prognostic value of node involvement after preoperative chemotherapy in 507 patients with operable breast cancer. Proc Am Soc Clin Oncol. 1998;17:
  28. Schwartzberg LS, Birch R, Weaver CH, Campos L, Buckner CD. High pathological complete response rate to sequential doxorubicin and paclitaxel primary chemotherapy for locally advanced breast cancer (LABC). Proc Am Soc Clin Oncol. 1998;17:
  29. Ellis P, Smith I, Ashley S. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol. 1998;16:107–114
  30. Jacquillat C, Weil M, Baillet F. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer. 1990;66:119–129
  31. Scholl SM, Pierga JY, Asselain B. Breast tumour response to primary chemotherapy predicts lovcal and distant control as well as survival. Eur J Cancer. 1995;31A:1969–1975
  32. Colleoni M, Nole F, Minchella I. A. Pre-operative chemotherapy and radiotherapy in breast cancer. Eur J Cancer. 1998;34:641–645
  33. Abraham DC, Jones RC, Jones SE. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer. 1996;72:91–100
  34. Therasse P, Mauriac L, Welnicka M. Neo-adjuvant dose intensive chemotherapy in locally advanced breast cancer (LABC): an EORTC-NCIC-SAKK randomized phase III study comparing FEC (5FU, epirubicin, cyclophosphamide) vs high dose intensity EC + G-CSF (filgrastim). Proc Am Soc Clin Oncol. 1998;17:
  35. Ayash LJ, Elias P, Ibrahim J. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol. 1998;16:1000–1007
  36. Diéras V, Fumoleau P, Romieu G. A randomized parallel study of doxorubicin/taxol (AT) and doxorubicin/cyclophosphamide (AC) as neoadjuvant treatment of breast cancer. Breast Cancer Res Treat. 1998;50:
  37. Frassoldati A, Banzi MC, Romagnoli R, Silingardi V. Primary chemotherapy with adriamycin and paclitaxel in breast cancer. Proc Am Soc Clin Oncol. 1998;17:
  38. Cameron DA, Anderson EDC, Levack P. Primary systemic therapy for operable breast cancer – 10-year survival data after chemotherapy and hormone therapy. Br J Cancer. 1997;76:1099–1105
  39. Gazet JC, Coombes RC, Ford HT. Assessment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer. Br J Cancer. 1996;73:758–762
  40. Mauriac L, Durand M, Bonichon F, Floquet A. First line tamoxifene for invasive hormonal sensitive non metastatic breast carcinomas in young postmenopausal patients. Eur J Cancer. 1996;32A:
  41. Buzdar A, Hortobagyi G. Update on endocrine therapy for breast cancer. Clin Cancer Res. 1998;4:527–534
  42. Soubeyran I, Quénel N, Coindre JM. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Br J Cancer. 1996;74:1120–1125
  43. Chevillard S, Pouillart P, Beldjord C. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer. 1996;77:292–300
  44. MacGrogan G, Mauriac L, Durand M. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GSTπ. Br J Cancer. 1996;74:1458–1465
  45. Pierga JY, Lainé-Bidron C, Beuzeboc P, De Crémoux P, Pouillart P, Magdelénat H. Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer. Br J Cancer. 1997;76:537–540
  46. Remvikos Y, Beuzeboc P, Zadjela A, Voillemot N, Magdelenat H, Pouillart P. Correlation of pretreatment prolferative activity of breast cancer with response to cytotoxic chemotherapy. J Natl Cancer Inst. 1989;81:1383–1387
  47. Collecchi P, Baldini E, Giannessi P. Primary chemotherapy in locally advanced breast cancer (LABC): Effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers. Eur J Cancer. 1998;34:1701–1704
  48. Rasbridge SA, Gillett CE, Seymour AM. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer. 1994;70:335–341
  49. Chang J, Powles TJ, Allred DC. Predictive molecular markers for clinical outcome following primary chemotherapy for operable breast cancer. Proc Am Soc Clin Oncol. 1998;17:
  50. Kandioler-Eckersberger D, Taucher S, Steiner B. P53 genotype and major response to anthracyclin or paclitaxel based neoadjuvant treatment in breast cancer patients. Proc Am Soc Clin Oncol. 1998;17:
  51. Lancet. 1998;352:930–942
  52. Lancet. 1998;351:1451–1467

☆ Corresponding author: Etienne GC Brain, Department of Medical Oncology, Cancer Centre René Huguenin, 35, rue Dailly, 92210 Saint-Cloud, France, Tel +33 1 47 11 15 15 Fax +33 1 47 11 16 29 E-mail ecg_brain@yahoo.com

PII: S0305-7372(98)90118-9

doi: 10.1053/ctrv.1998.0118

Cancer Treatment Reviews
Volume 25, Issue 4 , Pages 187-197 , August 1999

Article Tools